The Central Government on Monday said that more than 12.07 crore balance and unutilized COVID-19 vaccine doses are still available with the States and Union Territories (UTs).
The Drugs Controller General of India (DCGI) on Thursday granted conditional regular market approval for COVID-19 vaccines Covaxin and Covishield for restricted use in emergency situations in the adult population.
The Serum Institute of India (SII) has sought India’s drug regulator’s approval for the Covishield vaccine as a booster dose citing adequate stock of the vaccine in the country, officials informed on Thursday.
United Kingdom government on Wednesday in its revised travel advisory said that Covishield is qualified as an approved vaccine.
The European Medicines Agency (EMA) said it has not received any application from the COVID-19 vaccine Covishield maker Serum Institute of India (SII) for authorisation.
Government-run COVID-19 vaccination centres across the national capital are facing vaccination shortages, especially of Covishield, and several people are worried that they are going to miss their scheduled date for the second shot.
Amidst the shortage of vaccines in Telangana, 50 vials of Covishield vaccine were found to be missing from Area Hospital in Kondapur of Ranga Reddy District in Telangana.
The National Technical Advisory Group on Immunisation (NTAGI) on Thursday recommended an increase in the gap between two doses of Serum Institute of India’s COVISHIELD to 12-16 weeks.
External Affairs Minister (EAM) S Jaishankar on Wednesday explained the difference between India’s vaccine “production situation”, from that of the US and said Covishield is being made in India due to its efficient production venue.
English
English
English
